Literature DB >> 23246372

Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways.

E R Gimba1, T M Tilli.   

Abstract

Human osteopontin is subject to alternative splicing, which generates three isoforms, termed OPNa, OPNb and OPNc. These variants show specific expression and roles in different cell contexts. We present an overview of current knowledge of the expression profile of human OPN splicing isoforms (OPN-SIs), their tissue-specific roles, and the pathways mediating their functional properties in different pathophysiological conditions. We also describe their putative application as biomarkers, and their potential use as therapeutic targets by using antibodies, oligonucleotides or siRNA molecules. This synthesis provides new clues for a better understanding of human OPN splice variants, their roles in normal and pathological conditions, and their possible clinical applications.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246372     DOI: 10.1016/j.canlet.2012.12.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  49 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

3.  Noncontiguous Protein Interaction Domains in Osteopontin Contribute to Enhance HIV-1 Replication.

Authors:  Caitlin Eger; Kimberly Cirelli; Jessica Budiaman; Amanda Brown
Journal:  J Hum Virol Retrovirol       Date:  2014-05-23

4.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

5.  Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling.

Authors:  Xin Duan; Mu Qiao; Fengfeng Bei; In-Jung Kim; Zhigang He; Joshua R Sanes
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

Review 6.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

7.  Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle.

Authors:  Charles N Pagel; Dimuthu K Wasgewatte Wijesinghe; Neda Taghavi Esfandouni; Eleanor J Mackie
Journal:  J Cell Commun Signal       Date:  2013-12-08       Impact factor: 5.782

Review 8.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

Review 9.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

10.  Intranasal administration of vitamin D attenuates blood-brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats.

Authors:  Budbazar Enkhjargal; Devin W McBride; Anatol Manaenko; Cesar Reis; Yasushi Sakai; Jiping Tang; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.